The 'Million Women' Study should not change HRT prescription

Maturitas

Volumn 46, Issue 2, 2003, Pages 97-98

  Palacios, Santiago ^a  

^a Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GESTAGEN; HORMONE;

BREAST CANCER; BREAST TUMOR; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; DRUG USE; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; IATROGENIC DISEASE; MAMMOGRAPHY; MENOPAUSE; NOTE; PRESCRIPTION; RISK BENEFIT ANALYSIS; RISK FACTOR; SPAIN; STUDY; TUMOR; UTILIZATION REVIEW;

EID: 0141922927     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.09.005     Document Type: Note

References (4)

1. Breast cancer and hormone replacement therapy in the 'Million Women' Study. Million Women Study Collaborators. Lancet 2003;362:419-27.
2. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 350:1997;1047-1059.
3. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomised trial. J. Am. Med. Assoc. 289:2003;3243-3253.
4. Marchant D.J. Risk factors. Obstet. Gynecol. Clin. North Am. 21:(4):1994;561-586.